- Market Realist•14 hours ago
Roche’s (RHHBY) HER2+ (human epidermal growth factor receptor 2-positive) franchise includes its blockbuster drug, Herceptin, as well as Perjeta and Kadcyla.
- Market Realist•17 hours ago
Roche Holding (RHHBY) reported earnings for 3Q16 on October 20, 2016. Wall Street analysts expected Roche to report 12.6 billion Swiss francs in revenue during 3Q16 while the company reported ~12.5 billion ...
Roche Holding AG (RHHBY)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||0.00 - 0.00|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||21.73|
|Avg Vol (3m)||996,729|
|Dividend & Yield||1.02 (3.48%)|